Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 11, 2020, the Compensation Committee of the Board of Directors approved "inducement" grants to 31 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Pasadena. CA | Posted on March 17th, 2020

The option grants entitle the employees, in aggregate, to purchase up to 164,000 shares of common stock and receive up to 205,000 restricted stock units. The strike price of the options is set at an exercise price per share of $28.56, the last reported closing price of the Company's common stock on March 11, 2020, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company’s common stock on the date of hire of 15 new employees, anticipated to be within two months of the date of the approval. The grants are outside of the Company's stockholder-approved equity incentive plans. The options vest and become exercisable over a period of four years. The RSUs vest annually over either one to four years.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

CEA-Leti Reports Machine-Learning Breakthrough That Opens Way to Edge Learning: Article in Nature Electronics Details Method that Takes Advantage of RRAM Non-Idealities To Create Intelligent Systems that Have Potential Medical-Diagnostic Applications January 20th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results January 20th, 2021

Scientists synthetize new material for high-performance supercapacitors January 19th, 2021

Keeping the costs of superconducting magnets down using ultrasound: Scientists show ultrasonication is a cost-effective approach to enhance the properties of magnesium diboride superconductors January 15th, 2021

Investments/IPO's/Splits

180 Degree Capital Corp. Effects 1-for-3 Reverse Stock Split January 4th, 2021

180 Degree Capital Corp. Announces the Initiation of Repurchases under Its $2.5 Million Stock Buyback Program, a 1-for-3 Reverse Stock Split, and Q4 2020 Updates December 22nd, 2020

180 Degree Capital Corp. Reports +7.4% Growth and $2.90 Per Share NAV as of September 30, 2020, and Developments From Q4 2020 November 19th, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results November 3rd, 2020

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results January 20th, 2021

Chemists invent shape-shifting nanomaterial with biomedical potential It converts from sheets to tubes and back in a controllable fashion January 13th, 2021

Nanocrystals that eradicate bacteria biofilm January 8th, 2021

Detecting COVID-19 antibodies in 10-12 seconds January 8th, 2021

Announcements

CEA-Leti Reports Machine-Learning Breakthrough That Opens Way to Edge Learning: Article in Nature Electronics Details Method that Takes Advantage of RRAM Non-Idealities To Create Intelligent Systems that Have Potential Medical-Diagnostic Applications January 20th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results January 20th, 2021

Scientists synthetize new material for high-performance supercapacitors January 19th, 2021

Keeping the costs of superconducting magnets down using ultrasound: Scientists show ultrasonication is a cost-effective approach to enhance the properties of magnesium diboride superconductors January 15th, 2021

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results January 20th, 2021

Chemists invent shape-shifting nanomaterial with biomedical potential It converts from sheets to tubes and back in a controllable fashion January 13th, 2021

Nanocrystals that eradicate bacteria biofilm January 8th, 2021

Detecting COVID-19 antibodies in 10-12 seconds January 8th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project